ACUTE-GO is a Study Testing the Effectiveness and Safety of Two Doses of Purified Cortrophin Gel in Patients With Acute Gouty Arthritis Flares (ACUTE-GO)
A Randomized, Multi-Center, Double-blind, Efficacy and Safety Study of Two Dose Levels of Purified Cortrophin® Gel in Patients With Acute Gouty Arthritis Flares
The goal of this clinical trial is to learn if Purified Cortrophin Gel can help people with acute gouty arthritis when they are having a sudden flare-up. It will also monitor participants for any potential side effects while on this therapy. The main question it aims to answer is: is there a change in gout pain intensity after receiving Purified Cortrophin Gel.
Researchers will compare two different doses of Purified Cortrophin Gel.
Participants will:
- Receive one injection of Purified Cortrophin Gel
- Have 2 in-person visits to the site and 3 virtual/telephone visits
- Complete daily surveys about their gout flare
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 4
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Ashley Gantt
- Telefonnummer: 678-527-1332
- E-post: ashley.gantt@anipharmaceuticals.com
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Mass General Hospital
-
Hovedetterforsker:
- Hyon K Choi, MD, DrPH
-
Ta kontakt med:
- Ana D Fernandes, MA
- Telefonnummer: 617-643-2140
- E-post: adfernandes@mgh.harvard.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Main inclusion criteria:
-
Signed informed consent to participate in this study.
-
Male and female patients, aged 18-90 years.
-
Meeting the 2015 Gout classification criteria of the ACR/EULAR collaborative initiative.
-
Onset of current acute gout flare within 5 days prior to study entry
-
Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS).
-
History of ≥ 1 gout flares within the 12 months prior to study entry
-
The patient meets at least one of the following criteria for NSAIDs or colchicine treatment options:
- Minimum of one episode of inadequate response to treatment.
- The investigator deems that the patient is either contraindicated or inappropriate for treatment with NSAIDs or colchicine. Inappropriateness could be due to anticipated changes in patient status (i.e., such as worsening of comorbidities or use of concomitant medication).
-
Patients must be willing and capable of using, and have access to, an electronic device (e.g., cellphone or internet connected computer/tablet) to be able to complete surveys.
Main exclusion criteria:
-
Patients with active or known history of scleroderma, osteoporosis, active or recurrent bacterial, fungal or viral infections, or ocular herpes simplex.
-
Recent surgery (within 2 weeks prior to randomization or have an unhealed operation wound(s)).
-
Patients with active or known history of a peptic ulcer, uncontrolled congestive heart failure, uncontrolled hypertension, or uncontrolled diabetes type 1 or 2, as deemed by investigator.
-
Patients with sensitivity to proteins derived from porcine sources.
-
Patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.
-
Active flare of rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at baseline.
-
Polyarticular gouty arthritis flare currently active in more than 4 joints.
-
Patients who have taken an investigational drug within five times the half-life of that investigational drug has passed or within 30 days of randomization.
-
Previous inclusion in this study.
-
Patients currently receiving dialysis.
-
Uncontrolled clinically significant hematologic, CNS, hepatic, pulmonary, gastrointestinal, metabolic, or endocrine disease as deemed by the investigator.
-
Presence of any medical or psychological condition or laboratory result that might create risk to the patients (or interfere with the patient's ability to comply with the protocol requirements, or to complete the study) in the opinion of the investigator.
-
Prior or current treatment with any ACTH product.
-
Pregnant or nursing (lactating) women. Women of childbearing potential are required to be using an acceptable method of contraception.
- Contraception must be used for the entire study and for at least 30 days after the last dose of study drug.
- Acceptable methods of contraception are:
i. hormonal methods, such as birth control pills, patches, injections, vaginal rings, or implants ii. barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm) iii. intrauterine device (IUD) iv. abstinence (no sex)
-
Patients taking urate-lowering therapy have to be on a stable dose and regimen for ≥2 weeks before entering the study and remain on a stable dosage and regimen for at least 1 week after Purified Cortrophin® Gel.
-
Use of specified pain relief medications or biologics (including glucocorticoids, narcotics, paracetamol/acetaminophen, NSAIDs, colchicine, IL-blockers and tumor necrosis factor [TNF] inhibitors) within specified periods prior to randomization.
-
Vaccination within 30 days prior to study enrollment and during the study period.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Aktiv komparator: 40 U Purified Cortrophin Gel
|
One injection of Purified Cortrophin Gel, 40 U |
|
Aktiv komparator: 80 U Purified Cortrophin Gel
|
One injection of Purified Cortrophin Gel, 80 U |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in gout pain intensity from baseline in the target joint following PCG administration.
Tidsramme: From baseline to Day 3
|
Change in gout pain intensity from baseline in the target joint following PCG administration measured by Visual Analog Scale (VAS) at 72 hours post-injection (Day 3) on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 = unbearable pain; higher scores indicate worse (more severe) pain. |
From baseline to Day 3
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration measured by Visual Analog Scale (VAS) at Day 1 (24 hours post-injection)
Tidsramme: Baseline to Day 1
|
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration measured at Day 1 (24 hours post-injection) on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 |
Baseline to Day 1
|
|
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration as measured by Visual Analog Scale (VAS) at Day 2 (48 hours post-injection)
Tidsramme: Baseline to Day 2
|
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration as measured on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 = unbearable pain; higher scores indicate worse (more severe) pain. |
Baseline to Day 2
|
|
Change in pain intensity timeline at baseline, 24 hours, 48 hours, 72 hours, and Day 7 post-injection
Tidsramme: Baseline to Day 7
|
Baseline to Day 7
|
|
|
Time to onset of effect (≥20% change from baseline pain intensity on VAS)
Tidsramme: Baseline to Day 7
|
Baseline to Day 7
|
|
|
Time to response (≥50% change from baseline pain intensity on VAS)
Tidsramme: Baseline to Day 7
|
Baseline to Day 7
|
|
|
Patient Global Self-Assessment of Response to Treatment (5-Point Likert Scale)
Tidsramme: Baseline to Day 7
|
Patient Global Self-Assessment of Response to Treatment (5-Point Likert Scale) 24 hours, 48 hours, 72 hours, and Day 7 post-injection scored 0 (Poor) to 4 (Excellent); higher scores indicate a better response. |
Baseline to Day 7
|
|
Physician-Assessed Inflammatory Signs of the Index Joint (Joint Tenderness, Swelling, Range of Motion, and Erythema)
Tidsramme: Baseline to Day 3
|
Investigator-assessed composite of inflammatory signs in the index (most affected) joint, evaluated at baseline (Day 0) and 72 hours post-injection (Day 3): Joint tenderness - assessed via palpation/passive motion on a 4-point Likert scale: 0 (no pain) to 3 (severe/patient winces and withdraws); lower scores indicate better outcome. Joint swelling - 4-point Likert scale: 0 (no swelling) to 3 (severe swelling/bulging beyond joint margins); lower scores indicate better outcome. Target joint range of motion - 5-point Likert scale: 0 (normal) to 4 (immobilized); lower scores indicate better outcome. Erythema - categorical assessment: present, absent, or not assessable. |
Baseline to Day 3
|
|
Physician assessment of local tolerability at injection site (at 72 hours post-injection) - Number of Participants with Injection Site Reactions (Adverse Events)
Tidsramme: Baseline to Day 3
|
Local tolerability at the injection site will be assessed via investigator-reported adverse events. Injection site reactions occurring after study drug administration will be captured. The AE will be graded based on severity: MILD/MODERATE/SEVERE and causality: related/not related to study drug. |
Baseline to Day 3
|
|
Physician's Global Assessment of Response to Treatment (5-Point Likert Scale)
Tidsramme: Baseline to Day 3
|
Physician's Global Assessment of Response to Treatment (5-Point Likert Scale) scored 0 (Poor) to 4 (Excellent); higher scores indicate a better response. |
Baseline to Day 3
|
|
Use of rescue medication (up to 72-hours post-injection)
Tidsramme: Baseline to Day 3
|
Baseline to Day 3
|
|
|
Safety and Tolerability Assessments (Adverse Events, Serious Adverse Events, Clinical Laboratory Parameters, and Vital Signs)
Tidsramme: Baseline to Day 7
|
Safety will be assessed as follows: Adverse Events (AEs) and Serious Adverse Events (SAEs) - collected from study drug administration through Day 7, graded by the investigator as MILD, MODERATE, or SEVERE, and assessed for causality (related/not related to study drug). Clinical laboratory safety parameters - collected at baseline (Day 0) and Day 3, including biochemistry (AST, ALT, total bilirubin, ALP, PT/INR, albumin, total/LDL/HDL cholesterol, triglycerides, creatinine, sodium, potassium, ferritin, uric acid, glucose, HbA1c, troponin T, CRP, calcium, magnesium), hematology (hemoglobin, hematocrit, WBC with differential, platelets, ESR), and urinalysis (albumin, erythrocytes, hCG where applicable). Vital signs - systolic and diastolic blood pressure (mmHg), heart rate (bpm), and body temperature (°F), collected at baseline (Day 0) and Day 3, following a 5-minute rest period. |
Baseline to Day 7
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in Serum C-Reactive Protein (CRP) Level
Tidsramme: Baseline to Day 3
|
Levels of C-reactive protein inflammatory markers (baseline [Day 0], 72 hours [Day 3]) continuous biomarker in mg/L (confirm units with your lab). Increasing CRP reflects worsening inflammation |
Baseline to Day 3
|
|
Change from Baseline in Gout Attack Intensity Score (GAIS)
Tidsramme: Baseline to Day 3
|
Change from baseline in health-related quality-of-life Gout Attack Intensity Score (GAIS) at Day 0 and at Day 3 (72-hours post-injection). GAIS is the mean of 3 patient-reported items (pain, tenderness, swelling), each scored 1-5; range 1-5, with higher scores indicating worse (more severe) gout attack intensity. |
Baseline to Day 3
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Krystallarthropatier
- Muskel- og skjelettsykdommer
- Leddgikt
- Leddsykdommer
- Revmatiske sykdommer
- Purin-Pyrimidin-metabolisme, medfødte feil
- Metabolisme, medfødte feil
- Genetiske sykdommer, medfødte
- Metabolske sykdommer
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Ernæringsmessige og metabolske sykdommer
- Gikt
Andre studie-ID-numre
Andre studie-ID-numre
- ANI-PCG-003
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .